We can’t show the full text here under this license.
Spleen-focused NeoPol-mL242 mRNA vaccine triggers strong T-cell responses in liver cancer models
Updated
Abstract
Essence
A spleen-targeted NeoPol-mL242 showed anti-tumor immune activity in a model.
Evidence
This was a preclinical formulation and cancer-vaccine experiment using an ionizable lipid nanoparticle platform and an HCC model.
Caveat
The evidence is limited to model-system testing, so human efficacy, delivery behavior, and safety remain unproven.
Simplified
Key numbers
~ 90%
Tumor Burden Reduction
Compared to control groups receiving no treatment.
3.5%
CD8 T-cell Infiltration Increase
CD8 T-cell activation in treated versus control groups.